You are here

Article Text

Article menu
Download PDFPDF
Miscellanea
Journal club
Is ERCC1 a reliable prognostic protein biomarker in non-small-cell lung cancer?
  1. Hannah J Durrington
  1. Correspondence to Dr Hannah J Durrington, NIHR Clinical Lecturer in Respiratory Medicine, University of Manchester, AV Hill Building, Oxford Road, Manchester M13 9PT, UK; hannahd{at}doctors.org.uk

https://doi.org/10.1136/thoraxjnl-2013-204086

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    After resection for non-small-cell lung cancer (NSCLC) cisplatin-based postoperative chemotherapy may be administered. How do we predict which patients will benefit from cisplatin chemotherapy?

    This group previously published that the excision repair cross-complementation group 1 (ERCC1) protein acts as a prognostic biomarker, predicting the benefit of cisplatin-based chemotherapy after NSCLC resection. ERCC1 plays a crucial role in repairing DNA structures, damaged by cisplatin-based chemotherapy. Using immunohistochemical analysis, patients …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Not commissioned; internally peer reviewed.